{
    "Trade/Device Name(s)": [
        "Simplexa Flu A/B & RSV Direct Gen II",
        "Simplexa Flu A/B & RSV Positive Control Pack"
    ],
    "Submitter Information": "DiaSorin Molecular LLC",
    "510(k) Number": "K201505",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OCC",
        "OOI"
    ],
    "Summary Letter Date": "June 4, 2020",
    "Summary Letter Received Date": "June 5, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3980"
    ],
    "Regulation Name(s)": [
        "Respiratory Viral Panel Multiplex Nucleic Acid Assay"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A virus",
        "Influenza B virus",
        "Respiratory Syncytial Virus (RSV)"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON MDX"
    ],
    "Method(s)/Technology(ies)": [
        "Multiplex nucleic acid assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Control Pack"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin Molecular Simplexa Flu A/B & RSV Direct Gen II multiplex nucleic acid assay and Positive Control Pack for respiratory virus detection",
    "Indications for Use Summary": "Differential diagnosis of influenza A, influenza B, and RSV viral infections in humans using nasopharyngeal swab specimens with the LIAISON MDX instrument; the Positive Control Pack is for quality control with the associated assays.",
    "fda_folder": "Microbiology"
}